Q-omics provides the consensus-scored ANKRD34A profile across patient tissues and cancer cell-line models. ANKRD34A expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, ANKRD34A is differentially expressed in 10, with the highest sampling consensus in KIRP. Additionally, ANKRD34A RNA expression shows 18,352 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight UVM, KIRP, and ACC as cancer lineages where ANKRD34A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ANKRD34A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ANKRD34A survival associations across molecular data types. ANKRD34A RNA expression shows survival associations in the most cancer types (23), followed by mutation status (5) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ANKRD34A RNA expression–survival associations across cancer types. High ANKRD34A expression shows unfavorable associations in UVM, KIRP, ACC and DLBC, but favorable associations in PAAD and GBM. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for ANKRD34A RNA expression.
This table summarizes ANKRD34A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 1. The strongest signals are observed in LIHC for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for ANKRD34A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ANKRD34A shows lower tumor expression in THCA and higher tumor expression in KIRP, LUAD, LIHC, KIRC and BLCA. The KIRP box plot shows higher ANKRD34A RNA expression in tumor versus normal tissue (log2 FC = +0.597, t-test p = .001).
This table shows molecular features associated with ANKRD34A in patient tissues and cancer cell lines. In patient samples, ANKRD34A shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, ANKRD34A RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUAD and SOFT_TISSUE.
